Compare Hims and Hers Health Inc (HIMS) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Inovio Pharmaceuticals Inc — how do they compare? Hims and Hers Health Inc trades at $30.46 (market cap $7.12B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Hims and Hers Health Inc is far larger — about 90.6× Inovio Pharmaceuticals Inc's market cap, and Hims and Hers Health Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| HIMS | INO | |
|---|---|---|
Market Cap | $7.12B | $78.55M |
Sector | Health | Health |
52-Week High | $62.76 | $2.87 |
52-Week Low | $14.52 | $0.66 |
Enterprise Value | $7.82B | $49.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HIMS stock trades at $30.00, down 5.57% amid mixed Q2 2026 results. Revenue growth remains strong, with a 2026 outlook raised to $3.1B-$3.3B, but profitability is pressured by margin compression and a wider-than-expected quarterly loss. Technical indicators are neutral to bearish, with the price near key support at $30. Recent news highlights an FTC investigation and class-action lawsuits as headwinds.
The investment outlook is cautious. Growth prospects from subscriber gains and AI integration are offset by significant margin challenges and regulatory risks. Analyst consensus is a Hold with a $33.00 price target, suggesting limited near-term upside amid profitability concerns and negative free cash flow trends.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
